**To the Editor:** *Acinetobacter* spp. have emerged as a cause of nosocomial infections, especially in intensive care units (ICUs). In South Korea, *Acinetobacter* spp. was ranked as the third most frequently found pathogen in ICUs ([@R1]). With the emergence of multidrug-resistant (MDR) or pandrug-resistant (PDR) isolates, few drugs are now available to treat MDR or PDR *Acinetobacter* infections; polymyxins are the only therapeutic option in many cases ([@R2]). Current polymyxin resistance rates among *Acinetobacter* isolates are low worldwide ([@R3]). We report the emergence of extreme drug resistance (XDR) in *A. baumannii* isolates from patients in ICUs of Samsung Medical Center in Seoul, South Korea. These isolates were resistant to all tested antimicrobial drugs, including polymyxin B and colistin, to which PDR isolates are normally susceptible.

Sixty-three nonduplicate *Acinetobacter* spp. isolates were collected from the ICUs from April through November 2007. Species identification was performed based on partial RNA polymerase β-subunit gene sequences, amplified rDNA restriction analysis, and the gyrase B gene--based multiplex PCR method ([@R3]). Forty-four isolates were identified as *A. baumannii*: 9 as genomic species 3, six as genomic species 13TU, 2 as *A. baumannii*-like species, and 1 each as *A. junnii* and genomic species 10.

In vitro susceptibility testing was performed and interpreted by using the broth microdilution method according to the Clinical and Laboratory Standards Institute guidelines ([@R4]). Colistin and polymyxin B resistances were defined as MIC [\>]{.ul}4 mg/L ([@R4]). MDR was defined as characterized by resistance to [\>]{.ul}3 classes of antimicrobial drugs, and PDR was defined as characterized by resistance to all antimicrobial drugs, regardless of colistin and polymyxin B susceptibility. XDR was defined as resistance to all antimicrobial drugs. Multilocus sequence typing (MLST) and pulsed-field gel electrophoresis (PFGE) were performed for all PDR isolates according to previously described methods ([@R5],[@R6]). Genes encoding oxacillinases, such as those classified as OXA-23-like, OXA-24/40-like, OXA-51-like, and OXA-58-like, were detected as previously described ([@R7]). PCR and sequence analyses were performed to detect and characterize the other antimicrobial resistance genes, according to methods reported ([@R8]).

Of 63 *Acinetobacter* isolates, 31.7% and 34.9% were resistant to imipenem and meropenem, respectively. Of the 63 isolates, 27.0% and 30.2% were resistant to polymyxin B and colistin, respectively. For the other antimicrobial drugs, *Acinetobacter* spp. isolates showed antimicrobial resistance rates \>50%. Nineteen isolates (30.2%), all belonging to *A. baumannii*, were PDR. Most of these PDR isolates (16/19, 84.2%) were collected from endotracheal aspirate, and others were from peritoneal fluid and sputum. When characterized by PFGE and MLST, all PDR isolates belonged to a single clone, ST22, and all contained the *bla*~OXA-23~ and *bla*~OXA-66~ genes. IS*Aba1* was detected upstream of *bla*~OXA-23~ and *bla*~OXA-66~ in all PDR isolates. In addition, most PDR isolates contained *bla*~TEM-116~, *bla*~PER-1~, and *bla*~ADC-29~ genes. TEM-116 is a point mutant derivative of TEM-1, Val84→Ile. All β-lactamase genes were located on a plasmid. Also, IS*Aba1* was located at the upstream of all the *bla*~ADC~, which was shown by PCR. However, none of the isolates had *bla*~CTX-M~, *bla*~VEB~, *bla*~IMP~, *bla*~VIM~, or *bla*~GIM~.

Of the PDR isolates, 8 were resistant even to colistin and polymyxin B. These 8 isolates also showed resistance to tigecycline (MICs 4 mg/L). Thus, they were resistant to all antimicrobial drugs tested in this study and were considered to have XDR. The underlying diseases of the patients whose isolates were examined varied ([Table](#T1){ref-type="table"}). Although 2 isolates with XDR were colonizers, 6 caused infections. All but 1 patient was treated with mechanical ventilation before isolation of the pathogen. Number of hospital days before isolation of *A. baumannii* was 13--256 days, and the number of ICU days before isolation was 2--38 days. Four patients were immunocompromised, and 3 had bacteremia. Among the patients with infections characterized by XDR, the overall 30-day mortality rate was 66.7%, and the infection-related 30-day mortality rate was 50.0%. All 8 isolates with XDR showed common characteristics: ST22 containing OXA-23, OXA-66, TEM-116, PER-1, and ADC-29.

###### Clinical characteristics of 8 patients infected with extremely drug-resistant *Acinetobacter baumannii* isolates, South Korea\*

  Strain no.   Patient age/sex   Underlying disease                 Infection†      Days before isolation   Concurrent bacteremia   30-d outcome   Infection-related death   
  ------------ ----------------- ---------------------------------- --------------- ----------------------- ----------------------- -------------- ------------------------- -----
  07AC--052    60 y/F            Acute myeloid leukemia             Pneumonia       15                      8                       No             Died                      Yes
  07AC--159    79 y/M            Lymphoma                           Pneumonia       35                      9                       No             Died                      No
  07AC--192    50 y/M            Status postliver transplantation   Pneumonia       256                     2                       Yes            Survived                  NA
  07AC--204    55 y/F            Steven-Johnson syndrome            Pneumonia       13                      13                      Yes            Survived                  NA
  07AC--336    16 mo/M           Medulloblastoma                    Pneumonia       32                      13                      Yes            Died                      Yes
  07AC--347    17 mo/M           Hepatoblastoma                     Pneumonia       135                     28                      No             Died                      Yes
  07AC--329    1 mo/F            Edward syndrome                    Colonization‡   33                      33                      NA             NA                        NA
  07AC--063    56 y/M            Lung cancer                        Colonization‡   26                      21                      NA             NA                        NA

\*ICU, intensive care unit; NA, not applicable. All but 1 patient (with strain 07AC--192) had mechanical ventilators. Four patients (with strains 07AC--159, 07AC--192, 07AC--336, and 07AC--063) were immunocompromised hosts who had daily administration of corticosteroid (\>20 mg/d of prednisolone or an equivalent drug) during \>2 wk and treatment with chemotherapy for an underlying malignancy during 1 month before hospital admission. †Infection is defined as invasion of the body tissues by microorganisms resulting in disease. ‡Colonization occurs when an agent's presence in a host does not cause a specific immune response or infection.

We report the emergence of XDR in PDR *A. baumannii* isolates in South Korea. Characteristics of PDR *A. baumannii* isolates suggest that they spread from a single clone. A single *A. baumannii* strain with XDR might evolve from the prevailing PDR *A. baumannii* and could disseminate in the ICU, probably after contamination of the hospital environment and by nosocomial transmission. In South Korea, a high resistance rate to imipenem and meropenem in *Acinetobacter* spp. isolates may lead to extensive use of polymyxins ([@R3]). Thus, we can hypothesize that the most prevalent carbapenem-resistant, or MDR *A. baumannii* clone, became PDR and then evolved into clones with XDR by acquisition of polymyxin resistance caused by antimicrobial pressure. Our investigation showed a simultaneous emergence of resistance to all antimicrobial agents available, including colistin, polymyxin B, and tigecycline. XDR poses serious problems in the treatment of patients with *A. baumannii* infections, especially given the slow development of new antimicrobial agents.
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